“What we’re seeing now, especially with immunotherapy and other advances in cancer treatments, is that many lung cancer patients are living longer,” says Raymond H. Mak, MD, a coauthor of the study and a thoracic radiation oncologist at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital in Boston, Massachusetts. “So it’s more important than ever to focus more on how to minimize the cardiac risks years after treating patients.” Dr. Mak, who also is senior physician and disease center leader in radiation oncology and thoracic oncology as well as an assistant professor of radiation oncology at Harvard Medical School in Cambridge, Massachusetts, points to recent clinical trials that report 5-year survival rates of 15% to 20% and median survivals of greater than 2 years for patients with stage III NSCLC.

中文翻译：

---

肺癌放疗可能会增加主要不良心脏事件的风险

“我们现在所看到的，尤其是在免疫疗法和癌症治疗方面的其他进步之后，许多肺癌患者的寿命更长了，”该研究的合著者、Dana 的胸部放射肿瘤学家 Raymond H. Mak 医学博士说。 - 法伯癌症研究所和马萨诸塞州波士顿的布里格姆妇女医院。“因此，在治疗患者多年后，更多地关注如何将心脏风险降至最低，比以往任何时候都更加重要。” Mak 博士也是放射肿瘤学和胸部肿瘤学的高级医师和疾病中心负责人，以及马萨诸塞州剑桥市哈佛医学院放射肿瘤学助理教授，他指出最近的临床试验报告了 5 年生存率。 III 期 NSCLC 患者的 15% 至 20% 和中位生存期超过 2 年。